Skip To Main Content
Alex Barenboim on Muck Rack

Alex Barenboim

As seen in: MDPI, EJSO - European Journal of Surgical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alex

Contact Alex, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

JCM | Free Full-Text | The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuvant FOLFIRINOX

|
By Alex Barenboim, Kapil Sahnan, Diego Mercer, Alex Gaffan
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Cancers | Free Full-Text | Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?

|
By Yossi Maman, Alex Barenboim, Yaacov Goykhman, Oz Yakir
| MDPI
Abstract : Simple Summary In this paper, we showed that only a minority of patients (23%) undergoing upfront pancreatic resection completed the planned 12 courses of FOLFIRINOX, and we delineated the reasons for not completing it. We showed that patients who received neoadjuvant treatment were significantly more likely to receive six treatment courses, and that those who received at least six courses had better overall survival than those who did not.
Open in Who Shared Issue with article?

Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis

|
By Elizabeth Cathedra, Ravit Geva, Alex Barenboim, Guy Lahat
| EJSO - European Journal of Surgical Oncology Verified
Publication HistoryPublished online: August 01, 2018Accepted: July 25, 2018; Received in revised form: July 1, 2018; Received: May 17, 2018;
Open in Who Shared Issue with article?
See all 3 articles